Co-prescription of gastroprotective agents in patients taking non-selective NSAIDs or COX-2 selective inhibitors: Analysis of prescriptions

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 11, 2010, Pages 735-743

  Pasina, L ^a   Nobili, A ^a   Tettamanti, M ^a   Riva, E ^a   Lucca, U ^a   Piccinelli, R ^b   Defendi, L ^b   Perego, L ^b   Lucifora, S ^b   Bulla, C ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Local Health Authority   (Italy)

Author keywords

Drug utilization study; Gastroprotective agents; Non steroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SAFETY; DRUG SELECTIVITY; DRUG UTILIZATION; FEMALE; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; ITALY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION SYSTEM; PHYSICIAN; PRESCRIPTION; PREVALENCE; STOMACH PROTECTION;

EID: 78649270967     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48735     Document Type: Article

References (33)

1. AIFA. L'uso dei farmaci in Italia. Rapporto nazionale anno 2009. http://www.agenziafarmaco.it /sites/default/files/Rapporto-OsMed-primi-9-mesi- 2009.pdf.
2. AIFA. Le Note AIFA per l'uso appropriato dei farmaci. 2008 http://www.agenziafarmaco.it./wscs-render-attachment-by-id/111.90291. 1168607405163575e.pdf?id = 111.88204.1168596628882.
3. Antman EM, Bennet JS, Daugherty A. Use of non-steroidal antiinflammatory drugs. Circulation. 2007; 115: 19.
4. Batuwitage BT, Kingham JGC, Morgan NE, Bartlett RL. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J. 2007; 83: 66-68. (Pubitemid 46253592)
5. BIF. Le note in aggiornamento: 1-66. Bollettino d'Informazione sui Farmaci 2008; XV n.1: 5-11. http://www.agenziafarmaco.it/allegati/bif1-08-note1- 66.pdf.
6. Cantor SB. Pharmacoeconomics of coxib therapy. J Pain Symptom Manage. 2002; 24: 28-37.
7. Chan FKL, Abraham NS, Scheiman JM. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Antiplatelet Agents. Am J Gastroenterol. 2008; 103: 2908-2918.
8. Chan FKL, Wong VWS, Suen BY, Wu JCY, Ching JYL, Tsui Hung LC et al. Combination of a cyclooxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double blind, randomized trial. Lancet. 2007; 369: 1621-1626.
9. Dieppe P, Bartlett C, Davey P, Doyal L, Ebrahim S. Balancing benefits and harms: the example of non-steroidal anti-inflammatory drugs. BMJ. 2004; 329: 31-33.
10. Drazen MJ. COX-2 inhibitors: a lesson in unexpected problems. N Engl J Med. 2005; 352: 11.
11. Dubois RW, Melmed GY, Henning JM, Laine L. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther. 2004; 19: 197-208.
12. Fendrick AM. Cost-effective use of NSAIDs: issues pertinent to coxib use in managed care. Am J Manag Care. 2002; 8: 529-541.
13. Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001; 345: 433-442.
14. Forgacs I. Overprescribing proton pump inhibitors. BMJ. 2008; 336: 2-3.
15. Formoso G, Menna A, Voci, C, Violante A, Magrini N. Do coxibs reduce prescription of gastroprotective agents? Results of a record linkage study. BioMed Central. Cost Effectiveness and Resource Allocation 2006; 4: 1-4. Doi: 10.1186/1478-7547-4-4. http://www.resource-allocation.com/content/4/1/4.
16. Graham D, Campen D, Hui R, Spence M, Cheetham C, Levy G et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and nonselective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005; 365: 475-481. (Pubitemid 40215729)
17. Hernandez-Diaz S, Rodriguez LAG. Association between non-steroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation. An overview of epidemiologic studies published in the 1990s. Arch Inten Med. 2000; 160: 2093-2099.
18. Hur C, Chan AT, Tramontano AC. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits and costs. Ann Pharmacother. 2006; 40: 1052-1063.
19. Jones R, Rubin G, Berenbaum F, Scheiman J. Gastrointestinal and cardiovascular risk of nonsteroidal anti-inflammatory drugs. Am J Med. 2008; 121: 464-474.
20. Juni P, Nartey L, Reichenbach S. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004; 364: 2021-2029. (Pubitemid 39593078)
21. Juni P, Rutjes AW, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs? BMJ. 2002; 324: 1287-1288.
22. Lanas A, Ferrandez A. Inappropriate prevention of NSAID-induced gastrointestinal events among long-term users in the elderly. Drugs Aging. 2007; 24: 121-131.
23. Maetzel A, Krahn M, Naglie G. The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis. Ottawa: Canadian Coordinating Office for Health Technology Assessment. Technology report no 23 2001.
24. Mamdani M, Warren L, Kopp A, Paterson JM, Laupacis A, Basset K, Anderson GM. Changes in rates of upper gastrointestinal hemorrhage after the introduction of cyclooxygenase-2 inhibitors in British Columbia and Ontario. CMAJ. 2006; 175: 1535-1538.
25. Marshall JK, Pellissier JM, Attard CL et al. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective. Pharmacoeconomics. 2001; 19: 1039-1049.
26. Moore RA, Derry S, Phillips CJ. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord. 2006; 7: 79.
27. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther. 2000; 25: 333-340.
28. NICE. The clinical effectiveness and cost effectiveness of celecoxib, rofecoxib, meloxicam and etodolac (cox II inhibitors) for rheumatoid arthritis and osteoarthritis. National Institute of Clinical Excellence; 2000. http://www.nice.org.uk/pdf/coxiihtareport.pdf.
29. Scurti V, Font M, Anecchino C. Epidemiologia della cronicità: definizioni, metodologia, scenari modello. Giornale italiano di Farmacia clinica. 2005; 19: 103-109.
30. Suh DC, Hunsche E, Shin HC. Co-prescribing of proton pump inhibitors among chronic users of NSAIDs in the UK. Rheumatology. 2008; 47: 458-463.
31. Vonkeman HE, Brouwers JRBJ, van de Laar MAFJ. Understanding the NSAID related risk of vascular events. BMJ. 2006; 332: 895-898. (Pubitemid 44365588)
32. Walker NM, McDonald J. An evaluation of the use of proton pump inhibitors. Pharmacy World & Science. 2001; 23: 116-117.
33. Zullo A, Hassan C, Campo SM. Bleeding peptic ulcer in the elderly: risk factors and prevention strategies. Drugs Aging. 2007; 24: 815-828.